Inhibikase Therapeutics, Inc. (IKT) Tops Q3 EPS by 1c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Nasdaq ends higher as AI heavyweights rebound ahead of midterm results
- Apple shares slip amid guidance for tightening margins, slowing services growth
- Rising shorts cool U.S. large-cap positioning, cutting liquidation risk: Citi
- Apple's 'unprecedented' memory warning adds fuel to wobbly Micron, SK hynix trade
- Palantir raises 2026 revenue outlook after quarterly revenue nearly doubles on AI
Tweet
Share
E-mailGet Alerts IKT Hot Sheet
Join SI Premium – FREE
Inhibikase Therapeutics, Inc. (NASDAQ: IKT) reported Q3 EPS of ($0.86), $0.01 better than the analyst estimate of ($0.87).
For earnings history and earnings-related data on Inhibikase Therapeutics, Inc. (IKT) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Ashland (ASH) Misses Q4 EPS by 16c ; Offers Guidance
- Essential Utilities, Inc. (WTRG) Tops Q3 EPS by 4c
- Varonis Systems (VRNS) Tops Q3 EPS by 6c
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
